Germline PALB2 mutations have also been reported in unselected female breast cancer cases, but at a lower prevalence (0.9%, 18 out of 1,918 in Finnish breast cancer cases [4]; 0.5%, 2 out of 356 in French-Canadian breast cancer patients aged <50 years old [5]; and 0.4%, 5 out of 1,403 in Australian breast cancer patients [6]). The gene discussed is PALB2; the disease is breast carcinoma.